Chrohn’s disease

New therapy developed by RTP biotech startup offers hope to sufferers of Crohn’s disease, colitis

Posted by WRAL News | Jun 10, 2021

The study, conducted by Gusto Global and UNC-Chapel Hill scientists, demonstrated that Gusto Global’s novel community of bacteria prevented and treated chronic immune-mediated colitis in “humanized” mouse models.

TARGET PharmaSolutions teams with Bristol-Myers Squibb on IBD Study

Posted by WRAL News | Dec 10, 2018

The two companies will team up on TARGET-IBD, a longitudinal observational study that evaluates patients with inflammatory bowel disease, including adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate colitis.

Chrohn’s disease

New therapy developed by RTP biotech startup offers hope to sufferers of Crohn’s disease, colitis

TARGET PharmaSolutions teams with Bristol-Myers Squibb on IBD Study

Categories

Tags